免疫检查点抑制剂在儿童恶性肿瘤中的局限性与机遇
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
作者信息
Park Jeong A, Cheung Nai-Kong V
机构信息
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pediatrics, Inje University Haeundae Paik Hospital, Busan, Republic of Korea.
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Cancer Treat Rev. 2017 Jul;58:22-33. doi: 10.1016/j.ctrv.2017.05.006. Epub 2017 Jun 1.
Abstract
Immune checkpoint inhibitors (ICI) have shown great promise in a wide spectrum of adult solid and hematological malignancies, achieving objective tumor responses and prolonging survival. However, there is limited clinical success amongst pediatric patients. In this review, we summarize the current understanding of ICI and present an up-to-date overview of recent and ongoing clinical trials of ICI in pediatric malignancies. In addition, we will discuss immunologic and clinical difficulties in this young population, as well as future prospects for combination of ICI with other immune-based and conventional treatments.
摘要
免疫检查点抑制剂（ICI）在多种成人实体瘤和血液系统恶性肿瘤中显示出巨大潜力，能够实现客观的肿瘤缓解并延长生存期。然而，儿科患者的临床疗效有限。在本综述中，我们总结了目前对ICI的认识，并对ICI在儿科恶性肿瘤中的近期和正在进行的临床试验进行了最新概述。此外，我们将讨论这一年轻人群中的免疫和临床难题，以及ICI与其他基于免疫和传统治疗方法联合应用的未来前景。
相似文献
1
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.免疫检查点抑制剂在儿童恶性肿瘤中的局限性与机遇
Cancer Treat Rev. 2017 Jul;58:22-33. doi: 10.1016/j.ctrv.2017.05.006. Epub 2017 Jun 1.
2
Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.精准医学时代的免疫检查点抑制剂：放射科医生应了解的内容。
Korean J Radiol. 2017 Jan-Feb;18(1):42-53. doi: 10.3348/kjr.2017.18.1.42. Epub 2017 Jan 5.
3
Recent advances in the clinical development of immune checkpoint blockade therapy.免疫检查点阻断疗法的临床开发进展。
Cell Oncol (Dordr). 2019 Oct;42(5):609-626. doi: 10.1007/s13402-019-00456-w. Epub 2019 Jun 14.
4
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.免疫肿瘤学的下一步：通过适当的患者选择和合理设计的联合策略增强抗肿瘤效果。
Ann Oncol. 2017 Jan 1;28(1):57-74. doi: 10.1093/annonc/mdw534.
5
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.PD-1 或 PD-L1 抑制剂联合治疗癌症。
Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23.
6
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.并非所有免疫检查点抑制剂都一样：癌症试验中免疫相关不良事件的荟萃分析和系统评价。
Crit Rev Oncol Hematol. 2017 Nov;119:1-12. doi: 10.1016/j.critrevonc.2017.09.002. Epub 2017 Sep 8.
7
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.下一代免疫检查点抑制剂：黑色素瘤中的PD-1/PD-L1阻断
Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29.
8
Cancer immunotherapy-related adverse events: causes and challenges.癌症免疫治疗相关不良反应：原因与挑战。
Support Care Cancer. 2020 Dec;28(12):6111-6117. doi: 10.1007/s00520-020-05705-5. Epub 2020 Aug 28.
9
Second- and third-generation drugs for immuno-oncology treatment-The more the better?免疫肿瘤治疗的第二代和第三代药物——越多越好？
Eur J Cancer. 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10.
10
Immune-Checkpoint Blockade Therapy in Lymphoma.淋巴瘤的免疫检查点阻断治疗。
Int J Mol Sci. 2020 Jul 30;21(15):5456. doi: 10.3390/ijms21155456.
引用本文的文献
1
Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the literature.免疫检查点抑制剂在儿童肝细胞癌中的安全性及临床疗效：一例病例报告并文献复习
Front Oncol. 2025 Aug 15;15:1576892. doi: 10.3389/fonc.2025.1576892. eCollection 2025.
2
Complete Response to Nivolumab and Ipilimumab After Pazopanib Discontinuation in a Seven-Year-Old Girl With Alveolar Soft Part Sarcoma: A Case Report and Literature Review.一名七岁肺泡软组织肉瘤女孩停用帕唑帕尼后对纳武单抗和伊匹单抗完全缓解：病例报告及文献综述
Cancer Rep (Hoboken). 2025 Aug;8(8):e70305. doi: 10.1002/cnr2.70305.
3
Biologically informed machine learning modeling of immune cells to reveal physiological and pathological aging process.基于生物学信息的免疫细胞机器学习建模，以揭示生理和病理衰老过程。
Immun Ageing. 2024 Oct 24;21(1):74. doi: 10.1186/s12979-024-00479-4.
4
Emerging druggable targets for immune checkpoint modulation in cancer immunotherapy: the iceberg lies beneath the surface.癌症免疫治疗中免疫检查点调节的新兴可用药靶：冰山在水面之下。
Apoptosis. 2024 Dec;29(11-12):1879-1913. doi: 10.1007/s10495-024-02022-8. Epub 2024 Oct 1.
5
Cancer immunotherapy of Wilms tumor: a narrative review.Wilms 瘤的癌症免疫疗法：叙述性综述。
Future Oncol. 2024;20(30):2293-2302. doi: 10.1080/14796694.2024.2386929. Epub 2024 Sep 5.
6
TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8 T cell priming.TLR5 激动剂联合抗 PD-1 治疗通过 M1/M2 巨噬细胞极化转变和 CD8 T 细胞的初始化增强抗肿瘤作用。
Cancer Immunol Immunother. 2024 Apr 17;73(6):102. doi: 10.1007/s00262-024-03679-5.
7
Update on immune-based therapy strategies targeting cancer stem cells.针对癌症干细胞的免疫治疗策略的最新进展。
Cancer Med. 2023 Sep;12(18):18960-18980. doi: 10.1002/cam4.6520. Epub 2023 Sep 12.
8
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma.T 细胞免疫疗法治疗骨肉瘤的前景与挑战。
Int J Mol Sci. 2023 Aug 7;24(15):12520. doi: 10.3390/ijms241512520.
9
Intratumoral erythroblastic islands restrain anti-tumor immunity in hepatoblastoma.肿瘤内红细胞岛抑制肝母细胞瘤中的抗肿瘤免疫。
Cell Rep Med. 2023 May 16;4(5):101044. doi: 10.1016/j.xcrm.2023.101044.
10
The peculiar challenge of bringing CAR-T cells into the brain: Perspectives in the clinical application to the treatment of pediatric central nervous system tumors.将嵌合抗原受体 T 细胞（CAR-T 细胞）引入大脑所面临的特殊挑战：在临床应用于治疗儿科中枢神经系统肿瘤方面的观点。
Front Immunol. 2023 Mar 21;14:1142597. doi: 10.3389/fimmu.2023.1142597. eCollection 2023.
本文引用的文献
1
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody.用新型HER2/CD3双特异性抗体克服对HER2靶向治疗的耐药性。
Oncoimmunology. 2017 Mar 10;6(3):e1267891. doi: 10.1080/2162402X.2016.1267891. eCollection 2017.
2
Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.接受免疫检查点抑制剂治疗的癌症患者的治疗相关死亡：一项系统评价和荟萃分析。
Clin Oncol (R Coll Radiol). 2017 Apr;29(4):218-230. doi: 10.1016/j.clon.2016.11.007. Epub 2016 Nov 25.
3
CAR T Cell Therapy for Solid Tumors.嵌合抗原受体 T 细胞疗法治疗实体瘤。
Annu Rev Med. 2017 Jan 14;68:139-152. doi: 10.1146/annurev-med-062315-120245. Epub 2016 Nov 17.
4
Severe cerebral edema following nivolumab treatment for pediatric glioblastoma: case report.纳武单抗治疗儿童胶质母细胞瘤后发生严重脑水肿：病例报告
J Neurosurg Pediatr. 2017 Feb;19(2):249-253. doi: 10.3171/2016.8.PEDS16326. Epub 2016 Nov 18.
5
Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.纳武单抗治疗难治性儿童霍奇金淋巴瘤
J Pediatr Hematol Oncol. 2017 Jul;39(5):e263-e266. doi: 10.1097/MPH.0000000000000703.
6
Overexpression of B7-H3 correlates with aggressive clinicopathological characteristics in non-small cell lung cancer.B7-H3的过表达与非小细胞肺癌侵袭性临床病理特征相关。
Oncotarget. 2016 Dec 6;7(49):81750-81756. doi: 10.18632/oncotarget.13177.
7
Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis.B7-H3与雄激素受体、免疫通路及前列腺癌不良预后的相关性：基于表达的分析
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):28-35. doi: 10.1038/pcan.2016.49. Epub 2016 Nov 1.
8
Clinical significance of tumor-infiltrating lymphocytes in breast cancer.乳腺癌肿瘤浸润淋巴细胞的临床意义。
J Immunother Cancer. 2016 Oct 18;4:59. doi: 10.1186/s40425-016-0165-6. eCollection 2016.
9
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.纳武单抗与标准化疗药物联合应用于晚期非小细胞肺癌患者的安全性和疗效：一项四臂Ib期研究。
Ann Oncol. 2016 Dec;27(12):2242-2250. doi: 10.1093/annonc/mdw416. Epub 2016 Oct 20.
10
T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.双特异性T细胞衔接器（BiTE）介导的针对CD19+儿童急性淋巴细胞白血病的T细胞反应受到白血病母细胞上PD-L1和CD80/CD86的相反调节。
Oncotarget. 2016 Nov 22;7(47):76902-76919. doi: 10.18632/oncotarget.12357.
Zotero 插件